Acute Bacterial Skin And Skin Structure Infections Market Size, Top Key Players, Growth, Trend Analysis And Forecast To 2033

The acute bacterial skin and skin structure infections market size has grown rapidly in recent years. It will grow from $10.57 billion in 2023 to $11.75 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to healthcare industry innovation, economic factors, patient population trends, evolving diagnostic methods, clinical trial innovation..

The acute bacterial skin and skin structure infections market size is expected to see strong growth in the next few years. It will grow to $17.17 billion in 2028 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to global epidemiological factors, market entry of new therapies, rapid diagnostic tools, patient-centric approach, shifting treatment guidelines.. Major trends in the forecast period include patient population demographics, antibiotic resistance concerns, advancements in treatment strategies, prevalence of methicillin-resistant staphylococcus aureus (mrsa), focus on outpatient treatment..

Market Overview -
Acute bacterial skin and skin structure infections (ABSSSIs) are a type of skin infection caused by bacteria that affect the skin and underlying tissues, leading to symptoms such as redness, swelling, pain, and warmth in the affected area. Medical interventions, such as antibiotic treatment, are used to prevent complications and promote healing in mild to severe infections.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13282&type=smp

Elevated Prevalence Of Skin Infections Fuels Growth In The Acute Bacterial Skin And Skin Structure Infections Market
The rising prevalence of skin infections is expected to propel the growth of the acute bacterial skin and skin structure infections market going forward. Skin infections are conditions in which microorganisms, such as bacteria, fungi, or viruses, invade and multiply within the skin, leading to various symptoms and discomfort. The rise in skin infections creates a greater demand for therapeutic solutions, antibiotics, and innovative treatments to address acute bacterial and skin structure infections, ensuring patients can access the best possible care and outcomes. For instance, in September 2022, according to the UK Health Security Agency (UKHSA), a UK-based national executive agency, the %age of Methicillin-resistant Staphylococcus aureus (MRSA) cases caused by skin and soft tissue infections increased to 33.7% in 2022 from 2021. Moreover, MRSA cases increased by 25.7% in the financial year from April 2020 to March 2021. Therefore, the rising prevalence of skin infections will drive the growth of the acute bacterial skin and skin structure infections market.

Competitive Landscape -
Major companies operating in the acute bacterial skin and skin structure infections market report are Pfizer Inc., AbbVie Inc., Novartis AG, Abbott Laboratories, Fresenius SE & Co. KGaA, GSK PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Menarini Group, Dr. Reddy's Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Lupin Limited, Zydus Lifesciences Limited, Eurofarma Laboratórios S.A., Glenmark Pharmaceuticals Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Alkem Laboratories Limited, Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Medicine Co. Ltd., Aurobindo Pharma Limited, Zhejiang Jingxin Pharmaceutical Co. Ltd., ACS Dobfar SpA, Melinta Therapeutics LLC, Shandong Luoxin Pharmaceutical Group Co. Ltd., Wakunaga Pharmaceutical Co. Ltd., Flynn Pharma Ltd.

Innovative Single Dose Therapies Transforming The Acute Bacterial Skin And Skin Structure Infection Treatment
Major companies operating in the acute bacterial skin and skin structure infections market are focused on developing innovative single-dose therapies, such as Dalbonova, to gain a competitive edge in the market. Dalbonova is a single-dose therapy that provides convenience and effectiveness so patients can achieve their desired results with just one potent 1500 mg dose administered once. For instance, in August 2023, BDR Pharmaceuticals Internationals Pvt. Ltd., an India-based pharmaceutical company that focuses on API (active pharmaceutical ingredient) and formulation therapeutic segments, including acute bacterial skin and skin structure infections, launched Dalbonova injection, a single-dose therapy for acute bacterial skin and skin structure infections (ABSSSI). Dalbonova Injection reduces the risk of hospital-acquired diseases By offering single-dose treatment and eliminating the need for hospital admissions. It is designed to treat acute bacterial skin and skin structure infections (ABSSSI) caused by certain gram-positive microorganisms in patients of all ages, including newborns.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/acute-bacterial-skin-and-skin-structure-infections-global-market-report

Key Segments -
The acute bacterial skin and skin structure infections market covered in this report is segmented -
1) By Type Of Infection: Hospital-acquired Acute Bacterial Skin And Skin Structure Infections, Community-acquired Acute Bacterial Skin And Skin Structure Infections
2) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline fosamil, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, Other Active Ingredients
3) By Route of Administration: Oral, Parenteral, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By Application: Cellulitis, Abscess, Surgical Wounds, Traumatic Wound

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.